Search
Celcuity Inc
CELCAdd to Watchlist
80.610USD
-4.300-5.06%
Close 09-18 16:00（ET）
3.95BMarket Cap
LossP/E TTM
After-hours 16:00 (ET)80.510USD+0.010+0.01%
After-hours 16:00 (ET)More Details of Celcuity Inc Company
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
Celcuity Inc Profile
Ticker SymbolCELC
Company nameCelcuity Inc
IPO dateSep 20, 2017
CEOSullivan (Brian F)
Number of employees87
Security typeOrdinary Share
Fiscal year-endSep 20
Address16305 36th Ave N Ste 100
CityMINNEAPOLIS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code55446-4285
Phone17633920767
Websitehttps://www.celcuity.com/
Ticker SymbolCELC
IPO dateSep 20, 2017
CEOSullivan (Brian F)
Company Executives of Celcuity Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.20M
+2.50%
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.20M
+2.50%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
80.56K
+1.90%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
80.56K
+1.90%
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
35.81K
+44.68%
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
35.81K
+44.68%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
8.29K
+18.46%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
8.29K
+18.46%
Dr. Polly A. Murphy, Ph.D.
Dr. Polly A. Murphy, Ph.D.
Independent Director
Independent Director
6.53K
+23.43%
Dr. Polly A. Murphy, Ph.D.
Dr. Polly A. Murphy, Ph.D.
Independent Director
Independent Director
6.53K
+23.43%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.20M
+2.50%
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.20M
+2.50%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
80.56K
+1.90%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
80.56K
+1.90%
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
35.81K
+44.68%
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
35.81K
+44.68%
FAQs
Who are the top five shareholders of Celcuity Inc?
The top five shareholders of Celcuity Inc are: Mr. Brian F. Sullivan
How many institutions hold shares of Celcuity Inc (CELC)?
As of 2026Q1, 415 institutions hold shares of Celcuity Inc, with a combined market value of approximately 47.21M, accounting for 97.67% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1586164.00.